Chemo-immunotherapy (Gemcitabine, Interferon-alpha 2b and p53 SLP) in Patients With Platinum-resistant Ovarian Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study investigates the feasibility and immunogenicity of the triple combination of
gemcitabine, Peg-Intron and p53 SLP vaccination in patients with platinum-resistant ovarian
cancer.